Crizotinib in Combination With Chemotherapy for Pediatric Patients With ALK+ Anaplastic Large-Cell Lymphoma: The Results of Children's Oncology Group Trial ANHL12P1.

Eric J LoweAnne F ReillyMegan S LimThomas G GrossLauren SaguiligDonald A Barkauskas Rui Wu Sarah Alexander Catherine M Bollard

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)

Arm CZ of ANHL12P1 demonstrated that the addition of CZ to standard treatment prevented relapses during therapy for children with ALCL, MDD predicted EFS, and the addition of CZ resulted in unexpected thromboembolic events. Overall survival and EFS rates are consistent with the highest reported outcomes for children with ALCL.

Keyphrases

young adults
clinical trial
palliative care
single cell
advanced non small cell lung cancer
major depressive disorder
stem cells
randomized controlled trial
type diabetes
diffuse large b cell lymphoma
skeletal muscle
rectal cancer
childhood cancer